Holen Sie sich die Stockscreener-App
3.31
1.41%
0.046
Qualigen Therapeutics Inc Aktie (QLGN) Neueste Nachrichten
Qualigen Therapeutics (NASDAQ:QLGN) Stock Price Up 3.3% – Here’s Why - Defense World
Qualigen Therapeutics Faces Nasdaq Delisting Notification - MSN
Qualigen Therapeutics (NASDAQ:QLGN) Stock Price Down 2.1% – Should You Sell? - Defense World
Qualigen Therapeutics Receives Nasdaq Deficiency Notice - marketscreener.com
Qualigen Therapeutics, Inc. receives expected notification of de - GuruFocus
Qualigen Therapeutics receives Nasdaq notice regarding delayed Form 10-Q - MSN
Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q | QLGN Stock News - GuruFocus
Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q - The Manila Times
Qualigen Therapeutics, Inc. Receives Expected Notification Of Deficiency From Nasdaq Related To Delayed Filing Of Quarterly Report On Form 10-Q - marketscreener.com
Qualigen Therapeutics faces potential Nasdaq delisting - Investing.com
Qualigen Therapeutics, Inc. Faces Potential Delisting from Nasdaq Due to Filing Deficiency - Nasdaq
Qualigen Therapeutics, Inc. receives expected notification - GlobeNewswire
Qualigen Gets Nasdaq Warning: Missing Q1 Report Puts Stock Listing in Jeopardy - Stock Titan
Qualigen Therapeutics (QLGN) Faces Nasdaq Compliance Challenge | - GuruFocus
Qualigen Therapeutics, Inc. Receives Notification of Deficiency - GuruFocus
Qualigen Therapeutics Faces Nasdaq Delisting Threat - TipRanks
Qualigen Therapeutics, Inc. Faces Nasdaq Delisting Due to Late Filing of 2024 Form 10-K - Nasdaq
Qualigen Therapeutics, Inc. Receives Notification of - GlobeNewswire
Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K - TradingView
QLGN stock touches 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa
QLGN stock touches 52-week low at $2.9 amid market challenges - Investing.com India
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Qualigen Therapeutics Delays Yearly Financial Report - TipRanks
Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme - GlobeNewswire
Qualigen Therapeutics to acquire Marizyme in strategic move - Investing.com
Qualigen Therapeutics to acquire Marizyme in strategic move By Investing.com - Investing.com South Africa
Medical Breakthrough: Qualigen's Strategic Move to Transform $10B Heart Surgery Market - Stock Titan
Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Short Interest Up 49.4% in January - Defense World
Qualigen to invest in NanoSynex, stock tumbles 21% - MSN
Qualigen Therapeutics Invests in NanoSynex’s Growth - TipRanks
Qualigen to participate in next funding round for NanoSynex - GlobeNewswire
This Breakthrough Could Cut Antibiotic Testing Time in HalfQualigen's Strategic Investment - StockTitan
Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Driven by Rising Disease Prevalence; AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Qualigen Therapeutics (NASDAQ:QLGN) Stock Price Down 5.2% – Time to Sell? - Defense World
Qualigen Therapeutics (NASDAQ:QLGN) Shares Down 5.2% – Here’s Why - Defense World
Qualigen Therapeutics (NASDAQ:QLGN) Trading Down 7.8% – Time to Sell? - Defense World
SEC Form S-1 filed by Qualigen Therapeutics Inc. - Quantisnow
Qualigen Therapeutics Announces Regained Compliance with - GlobeNewswire
Univest Securities, LLC Announces Successful Closing of - GlobeNewswire
Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares - GlobeNewswire
Qualigen Therapeutics appoints new board member - Investing.com
Qualigen Therapeutics Appoints Graydon Bensler to Board - TipRanks
QLGN Stock Touches 52-Week Low at $3.71 Amid Market Challenges - Investing.com
Qualigen Therapeutics announces 1-for-50 reverse stock split - Investing.com
QLGN stock touches 52-week high at $5.05 amid market fluctuations - Investing.com
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 - GlobeNewswire
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG - openPR.com
QLGN stock touches 52-week low at $0.11 amid market challenges - Investing.com
Qualigen Therapeutics faces Nasdaq delisting notice - Investing.com
Qualigen Therapeutics appoints new leadership amid strategic shift By Investing.com - Investing.com South Africa
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel - GlobeNewswire
Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN) - Yahoo Finance
Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering - GlobeNewswire
Why Is Qualigen Therapeutics (QLGN) Stock Down 22% Today? - MSN
Why Is Qualigen (QLGN) Stock Up 141% Today? - TradingView
Qualigen Therapeutics Secures Loan and Expands Equity - TipRanks
Why Is Qualigen Therapeutics (QLGN) Stock Down 12% Today? - MSN
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session - MSN
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination - Yahoo Finance
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting - Yahoo Finance
0.34%
7.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):